Xlear与Dr. Ferrer BioPharma合作,向用户提供更佳鼻腔卫生体验

2022-05-19 网络 网络

新近对旨在增强治疗穿透性、由计算机引导的鼻腔内喷雾方案进行的研究显示,该方案对有效治疗新冠病毒感染、鼻炎和鼻窦炎具有重要意义

Xlear今天宣布与Dr. Ferrer BioPharma (DFBP)建立新的伙伴关系,这将使Xlear鼻腔喷雾剂成为首款部署GentleMist喷嘴的鼻腔卫生工具。研究显示,这种新一代鼻腔喷雾剂技术的化合物弥散和覆盖更优、用户体验更佳。

鼻腔清洗相关研究发现,鼻部和鼻腔灌洗是改善健康、获得良好感受的重要工具。大量临床和实验室研究显示,鼻腔卫生是抗击鼻炎及各类细菌和病毒感染的重要辅助手段。

欧洲医学会新发表的研究发现,GentleMist喷嘴可将鼻腔喷雾剂更均匀、更彻底地弥散到鼻部和鼻腔中。该研究还发现,与典型的喷鼻技术相比,该新款喷嘴更温和、可显著提升用户体验。

传统上,鼻腔喷雾剂仅有一种标准模式,即喷雾剂沿着喷雾方向直接向上射入气道。这款新型喷嘴则非常温和,喷雾以涡流/漩涡模式喷洒。对Xlear及其用户而言,这一点非常重要且有益,能够让Xlear的合剂(盐水、木糖醇和葡萄柚籽提取物)更有效、更完整地施用于鼻部和鼻腔。

Xlear首席执行官Nate Jones表示:“二十多年来,数百万人一直在使用我们的鼻腔喷雾剂并从中受益,我们非常高兴能向他们提供这项新技术,改善他们的用户体验。我们意识到,如果用户每天早晚清洗鼻腔,即使是最轻微的不适、刺激或受伤,我们也不会强求他们为了疗效而清洗鼻腔。如果我们每次洗手或刷牙时都会受伤,我们同样不会强求这么做。就像洗手、洗澡和刷牙一样,清洗鼻腔是让我们保持清洁和健康并且全天呼吸更顺畅的一层额外保护。”

Xlear的产品并非用于诊断、治疗、治愈或预防任何疾病。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787796, encodeId=7ca81e87796d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Aug 13 22:12:46 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908705, encodeId=97071908e058f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 15 19:12:46 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919445, encodeId=5bf31919445dd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Nov 19 07:12:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703605, encodeId=e5871e03605b6, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Sep 30 17:12:46 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707589, encodeId=30631e07589dc, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Sat Jun 11 09:12:46 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465904, encodeId=dfb51465904fa, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Sat May 21 07:12:46 CST 2022, time=2022-05-21, status=1, ipAttribution=)]
    2022-08-13 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787796, encodeId=7ca81e87796d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Aug 13 22:12:46 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908705, encodeId=97071908e058f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 15 19:12:46 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919445, encodeId=5bf31919445dd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Nov 19 07:12:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703605, encodeId=e5871e03605b6, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Sep 30 17:12:46 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707589, encodeId=30631e07589dc, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Sat Jun 11 09:12:46 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465904, encodeId=dfb51465904fa, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Sat May 21 07:12:46 CST 2022, time=2022-05-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787796, encodeId=7ca81e87796d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Aug 13 22:12:46 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908705, encodeId=97071908e058f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 15 19:12:46 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919445, encodeId=5bf31919445dd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Nov 19 07:12:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703605, encodeId=e5871e03605b6, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Sep 30 17:12:46 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707589, encodeId=30631e07589dc, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Sat Jun 11 09:12:46 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465904, encodeId=dfb51465904fa, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Sat May 21 07:12:46 CST 2022, time=2022-05-21, status=1, ipAttribution=)]
    2022-11-19 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787796, encodeId=7ca81e87796d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Aug 13 22:12:46 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908705, encodeId=97071908e058f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 15 19:12:46 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919445, encodeId=5bf31919445dd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Nov 19 07:12:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703605, encodeId=e5871e03605b6, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Sep 30 17:12:46 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707589, encodeId=30631e07589dc, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Sat Jun 11 09:12:46 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465904, encodeId=dfb51465904fa, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Sat May 21 07:12:46 CST 2022, time=2022-05-21, status=1, ipAttribution=)]
    2022-09-30 surilei
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787796, encodeId=7ca81e87796d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Aug 13 22:12:46 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908705, encodeId=97071908e058f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 15 19:12:46 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919445, encodeId=5bf31919445dd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Nov 19 07:12:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703605, encodeId=e5871e03605b6, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Sep 30 17:12:46 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707589, encodeId=30631e07589dc, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Sat Jun 11 09:12:46 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465904, encodeId=dfb51465904fa, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Sat May 21 07:12:46 CST 2022, time=2022-05-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787796, encodeId=7ca81e87796d7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sat Aug 13 22:12:46 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908705, encodeId=97071908e058f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Nov 15 19:12:46 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919445, encodeId=5bf31919445dd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Nov 19 07:12:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703605, encodeId=e5871e03605b6, content=<a href='/topic/show?id=0d2869594b' target=_blank style='color:#2F92EE;'>#ERR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6959, encryptionId=0d2869594b, topicName=ERR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72d30527892, createdName=surilei, createdTime=Fri Sep 30 17:12:46 CST 2022, time=2022-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707589, encodeId=30631e07589dc, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Sat Jun 11 09:12:46 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465904, encodeId=dfb51465904fa, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Sat May 21 07:12:46 CST 2022, time=2022-05-21, status=1, ipAttribution=)]
    2022-05-21 mnda

相关资讯

J Control Release:通过鼻腔喷入的给药方法有望减轻抗精神病药物的副作用

麦克马斯特大学(McMaster University)的一个神经科学家和工程师团队发明了一种鼻喷剂,可以将抗精神病药物直接输送到大脑。

卫生专业人士请求WHO指导民众用鼻腔喷雾剂抗击COVID-19大流行

“研究显示,鼻腔喷雾剂(例如Xlear)可降低COVID-19的传播和感染风险”

卫生专业人士请求CDC指导美国民众用鼻腔喷雾剂抗击COVID-19大流行

“研究显示,鼻腔喷雾剂(例如Xlear)可降低COVID-19的传播和感染风险”

Nat Commun:胰岛素,饭前一喷就能瘦?

许多人依赖注射胰岛素维持正常的血糖水平。在胰岛素给糖尿病带来巨大帮助近一个世纪后,这种激素开始有了引人注目的新用途。7月18日,一项发表在《自然通讯》的最新研究提到,没有糖尿病的人将来可能也会在进餐时使用胰岛素,只不过它将成为一种抑制食欲的鼻腔喷雾。

J Alzheimers Dis:鼻腔喷雾式胰岛素有效治疗痴呆症

近日,发表在国际杂志J Alzheimers Dis上的一篇研究报告中,来自美国威克森林浸信医学中心(Wake Forest Baptist Medical Center)的研究人员通过研究表示,一种人造胰岛素鼻腔喷雾运输装置或可有效改善成年痴呆症及轻度认知损伤个体的工作记忆以及其它的精神能力。 文章中,研究者对60名诊断为遗忘型轻度认知损害(MCI)或轻度至中度阿尔兹海默氏症痴呆(AD)患者进

鼻腔喷雾式胰岛素有效治疗痴呆症

近日,发表在国际杂志J Alzheimers Dis上的一篇研究报告中,来自美国威克森林浸信医学中心(Wake Forest Baptist Medical Center)的研究人员通过研究表示,一种人造胰岛素鼻腔喷雾运输装置或可有效改善成年痴呆症及轻度认知损伤个体的工作记忆以及其它的精神能力。 文章中,研究者对60名诊断为遗忘型轻度认知损害(MCI)或轻度至中度阿尔兹海

拓展阅读

ACAAI 2023:淡盐水冲洗鼻腔和漱口,可预防新冠感染!

针对上呼吸道的干预措施淡盐水冲洗鼻腔和漱口可能会减少与 COVID-19 相关的上呼吸道症状的发生频率和持续时间。

感染新冠后产生的鼻腔抗体可维持9个月

虽然血液抗体有助于控制疾病,但鼻腔抗体有助于将感染拒之门外,这些发现强调了开发鼻腔针对性疫苗的必要性。

医学美图 || 颅脑MR-T2对照图谱

颅脑MR-T2对照图谱

Otolaryngol Head Neck Surg:鼻腔疾病的治疗对睡眠质量的影响:系统回顾和元分析

鼻塞是耳鼻喉科实践中的最常见的症状之一,可由各种鼻科疾病引起。之前对鼻塞的两种常见病因的研究,即鼻炎和鼻中隔偏曲(NSD),阐述了它们在干扰睡眠方面的作用。这两种疾病会损害生活质量,它们可能通过结构和

鼻腔鼻窦胚胎性横纹肌肉瘤1例

患者女,20岁。因左眼突出流泪2周,左侧鼻塞1周就诊。专科检查:右侧鼻腔狭窄,左侧总鼻道见粉红色肉芽样新事物,表面光滑,可见血性分泌物。CT扫描:左侧筛窦、蝶窦、上颌窦及鼻腔内等低混杂密度影,相应区域窦壁、左侧眶内壁、前颅底及枕骨斜坡上方骨质破坏,左侧内直肌及视神经受压移位,左侧眼球突出(图1)。MRI扫描:左侧筛窦、蝶窦、上颌窦及鼻腔内见不规则状稍长T1等长T2信号影,增强扫描不均匀强化,左侧前

JAMA Otolaryngol Head Neck Surg:慢性喉炎与鼻腔因素相关性研究

过敏性喉炎由于其他原因引起的重叠临床表现而出现诊断不足的情况。鼻腔情况与慢性喉炎之间的相关性,包括过敏性喉炎,尚未见基于群体流行病学调查的相关报道。最近,有研究人员评估了慢性喉炎患病率与各种鼻腔症状和内窥镜发现的相关性,并鉴定了与慢性喉炎过敏性原因相关的特异性相关鼻腔因子。研究包括了11283名参与者,平均年龄(SD)为50.1(16.6)岁,其中6365(56.4%)名为女性。研究发现,总共有3